Oncology News

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant ovarian cancer (PROC), Rina-S achieved a confirmed objective response rate (ORR) of 45.9% (95% CI: 36.3–55.7), including five compl...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by...

NEW YORK & TORONTO--(BUSINESS WIRE)--Klick Health took center stage throughout the evening at last night’s Medical Marketing + Media (MM+M) Awards, receiving the Market Access Gold Agency of the Year title plus nine campaign accolades, including five Gold trophies for “867-5309” (Cancer Support Community), “Project Inchstone” (Nestlé Compleat), and “MODDEN 26” (The Derek Sheely Foundation). The agency’s Chief Medical Officer Holly Henry, PhD said, “This recognition is a testament to what happen...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Singleton Associates, P.A. (Singleton Associates), a Radiology Partners-affiliated practice, and Blue Cross and Blue Shield of Texas (BCBSTX) have reached a new multi-year agreement, effective November 1, 2026. This long-term agreement represents a significant achievement for patients, providers, and healthcare organizations across Texas, reflecting both organizations’ commitment to network stability, continuity of care and uninterrupted access to high-quality...

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that two presentations of new data from its ongoing Phase 1/2 study of imneskibart will be featured at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. One presentation will focus on promising Phase 2 results for imneskibart with avelumab in checkpoint inhibi...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation targeted therapies for cancer, today announced an upcoming poster presentation of preclinical data on PHST001 at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place from November 4-8 in Phoenix, AZ. PHST001 is a first-in-class anti-CD24 macrophage checkpoint inhibitor designed to restore immune recognition in the tumor microenvironment and is c...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. The clinical poster will review the featur...

VALENCIENNES, France--(BUSINESS WIRE)--Orano Med has inaugurated Europe’s first industrial-scale pharmaceutical facility dedicated to the production of lead-212-based radioligand therapies....

BOSTON--(BUSINESS WIRE)--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC...